Metastatic Pancreatic Exocrine Cancer


Metastatic Pancreatic Exocrine Cancer

PEC is a frequent cancer both in women and men representing in United States about the 3.1% of all cancer diagnosed. Curability rate are very low even when disease is at an early resectable stage with a 5-years overall survival. The 5-year survival rate for people with stage IA pancreatic cancer is about 14%. For stage IB cancer, the 5-yearsurvival rate is about 12%. For stage IIA pancreatic cancer, the 5-yearsurvival rate is about 7%. For stage IIB cancer, the 5-year survival rateis about 5%. The 5-year survival rate for stage III pancreatic cancer isabout 3%. Stage IV pancreatic cancer has a 5-year survival rate of about 1%. Still, there are often treatment options available for people with this stage of cancer. Standard systemic therapy depends from patients performance status and the objective of therapy (neaodjuvant or palliative) and is usually based in the palliative setting on gemcitabine that in pivotal studies gave a benefit in quality of life (and a benefit in overall survival when combined with albumin bended paclitaxel. A more aggressive combination is taken in consideration when a cytoreductive aim could carry out too radical surgery.

PEC survivors are very few in particular among those diagnosed with an un resectable disease, we report the case of a woman who had a clinical diagnosis of advanced PEC not histologically confirmed because of a negative/non-diagnostic FNAB and in remission after a short course of chemotherapy with gemcitabine.

Media Contact:


Pancreatic Disorder and therapy